Annals of Oncology
Publisher: Elsevier · ISSN 0923-7534 · 64 articles
- A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine–tipiracil with bevacizumab in patients with metastatic colorectal cancer☆
- Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW☆
- Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study
- Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy☆
- Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial
- Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020)
- From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology’s New Pillar
- A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: results of the international IROCAS study☆
- Efficacy and safety of risvutatug rezetecan versus gemcitabine–docetaxel in relapsed or refractory osteosarcoma: primary results from the ARTEMIS-011 phase III trial☆
- Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01
- Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study☆
- Final analysis of the Neotorch study: perioperative toripalimab in combination with chemotherapy for patients with stage Ⅱ/Ⅲ resectable non-small-cell lung cancer ☆
- CheckMate 8HW: one checkmate, several moves left
- Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER study
- Table of Contents
- Editorial Board
- Adjuvant olaparib in germline BRCA carriers: new certainties and remaining open questions from the updated OlympiA results
- SKYSCRAPER-07: falling short of the top
- Long-term benefit from immune checkpoint inhibition in squamous esophageal cancer
- TIGIT at a crossroads: lessons from SKYSCRAPER-03 in unresectable stage III NSCLC
- ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer
- Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial
- Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study☆
- Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study
- Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648
- SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation☆
- Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study
- Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)
- Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer
- Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study☆